BioMark SSAT1 LIQUID BIOPSY ASSAY

The active detection of enzymes with elevated levels of cancers.

Assay

BioMark SSAT1 LIQUID BIOPSY ASSAY

BioMark’s initial assay detects SSAT1, an enzyme with elevated levels in numerous cancers, using an FDA approved drug. The assay targets a well researched and understood metabolic pathway. BioMark is amongst a unique group of companies that uses a safe therapeutic agent for diagnostic indication. This assay (SSAT1) can be used as a non-invasive, cost effective red alert tool for physicians globally.

BioMark has completed a comprehensive set of trial and is currently assembling a submission package to Health Canada for market approval for this test which physicians can use as a screening test for Lung and Breast Cancer and help to assess the need for more definitive imaging or other molecular test.

There is compelling scientific evidence to suggest that the SSAT1 Assay can be expanded for Glioblastoma (GBM), Gastrointestinal, Prostate and Head and Neck Cancers.

biomark-diagnostics-ssat1-assay

Applications

Clinical Applications

  • Test as a “Red Alert”
  • Measure response to treatment
  • Monitor for recurrence for cancer survivors

Clinical Trials

Clinical Trials Completed or "In Progress"

Urinary Excretion of Acetylamantadine by Cancer Patients

Principal Investigator: Dr. Andrew Maksymiuk, MD, Cancer Care Manitoba

Status: Open. In the process of final submission to Health Canada

Urinary Excretion of Acetylamantadine by Cancer Patients in Bangladesh

Principal Investigator: Prof. (Dr.) Parveen Shahida Akhtar, Head of the Department, Medical oncology,National Institute of Cancer Research and Hospital, Dhaka, Bangladesh

Status: Completed.

Food Effects on the Pharmacokinetics of Amantadine

Principal Investigator: Prof. Zeneng Cheng, Hunan Tiger-xiangya Drug Evaluation center, China

Status: Completed.

Urinary Excretion of Acetylamantadine by Normal Healthy Volunteers

Principal Investigator: Dr. Bram Ramjiawan, Ph. D, St. Boniface Hospital and Research Centre

Status: Completed.

Spermidine/spermine N-acetyltransferase 1 (SSAT 1) Gene Expression in Human Cancer

Principal Investigator: Dr. Andrew Maksymiuk, MD, Cancer Care Manitoba

Status: Open.

Excretion of Acetylamantadine (AA) by Lung Cancer Patients During a Chemotherapy Regimen

Principal Investigator: Dr. Andrew Maksymiuk, MD, Cancer Care Manitoba
Co-Investigator: Dr. Daniel S. Sitar, Ph.D, University of Manitoba
Co-Investigator: Dr. Paramjit Tappia, Ph.D, Asper Clinical Research Institute

Status: Open. Mid point assessment to establish proof of concept and patients still being enrolled extended ethics approval

Sign up for the latest Biomark news

No paperwork, no hassle. We keep things digital, easy and regular.

*Zero Spam Policy. You will need to confirm your email address to receive our news to your inbox.

© 2021 BioMark Diagnostics Inc. All Rights Reserved. BioMark’s mission is to provide universal access to a new paradigm in cancer diagnostics using metabolomics.